Which medications in the drug class Mineralocorticoid Receptor Antagonists are used in the treatment of Chronic Kidney Disease (CKD)?

Updated: Jul 21, 2021
  • Author: Pradeep Arora, MD; Chief Editor: Vecihi Batuman, MD, FASN  more...
  • Print

Mineralocorticoid Receptor Antagonists

Mineralocorticoid receptor (MR) over activation is thought to contribute to fibrosis and inflammation in both epithelial (eg, kidney) and nonepithelial (eg, heart, blood vessels) tissues. MR-mediated sodium reabsorption in the kidneys is also inhibited. 

Finerenone (Kerendia)

Finerenone is a nonsteroidal, selective MR antagonist, which is activated by aldosterone and cortisol and regulates gene transcription. Finerenone has a high potency and selectivity for the MR and has no relevant affinity for androgen, progesterone, estrogen, and glucocorticoid receptors. It is indicated to reduce risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure in adults with CKD associated with type 2 diabetes 

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!